Julie Lao

Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

Linus S. Lin, Thomas J. Lanza, James P. Jewell et al. · Journal of Medicinal Chemistry · 2006 · 122 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents

Tung M. Fong, Xiao-Ming Guan, Donald J. Marsh et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 101 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

Christopher W. Plummer, Paul E. Finke, Sander G. Mills et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 56 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Differential effects of oxyntomodulin and GLP-1 on glucose metabolism

Xiaobing Du, Jennifer Kosinski, Julie Lao et al. · American Journal of Physiology-Endocrinology and Metabolism · 2012 · 54 citations

Life Sciences, Endocrinology, Physiology +17

Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor

Richard Z. Chen, Andrea Frassetto, Julie Lao et al. · European Journal of Pharmacology · 2008 · 41 citations

Medicine, Medicinal Chemistry, Pharmacology +11